AstraZeneca, a developer of prescription pharmaceuticals, opened its first clinical pharmacology unit (CPU) in the U.S. at the University of Pennsylvania’s Penn Presbyterian Medical Center.
The firm, which has offices in Westboro, will study the safety and toxicity of a medicine in the CPU, as well as the relationship between a given drug dose and its actions. The results of these tests will serve as an initial measure before the company ventures into deeper clinical studies. The new CPU also serves the needs of patients by allowing researchers to more quickly develop novel therapies for unmet medical needs.
Dr. Alan Hollister will head the CPU, and bring 8 years of experience in the pharmaceutical industry.Â
